Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Fate Therapeutics Inc (NASDAQ:FATE) Shares Purchased by State Street Corp
07:20am, Sunday, 07'th Jun 2020
State Street Corp raised its stake in Fate Therapeutics Inc (NASDAQ:FATE) by 3.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). T
Vivet Therapeutics meldete heute, dass sowohl die US-Food and Drug Administration (FDA) als auch die Europäische Kommission (EC) VTX-803, das zweite G
Stocks Trading Above 52 Week Low and Below 52 Week High: $IOVA $CRBP $FATE
02:15pm, Monday, 25'th May 2020
May 25, 2020 (The Market Signal via Comtex) --
Sector Reports was created as a platform to help investors find the best free Stock Reports on stocks they...
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
12:00am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
Fate Therapeutics Reports FDA Clearance For Investigational New Drug Application For FT538, CRISPR-Edited, iPSC-Derived Cell Therapy
12:21pm, Wednesday, 20'th May 2020Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy
12:00pm, Wednesday, 20'th May 2020
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the
Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock
10:18am, Friday, 15'th May 2020
This mid-cap biotech is developing a new type of cellular immunotherapy, and its potential has attracted the attention of many institutional investors.
HC Wainwright & Co. Initiates Coverage On Fate Therapeutics with Buy Rating, Announces Price Target of $42
11:30am, Wednesday, 13'th May 2020Fate Therapeutics Inc (FATE) Q1 2020 Earnings Call Transcript
08:30pm, Tuesday, 12'th May 2020
Good afternoon, and thanks everyone for joining us for the Fate Therapeutics first quarter 2020 financial results call. Additionally, it is one of the first ever clinical trials of a cell therapy to
Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering
05:40pm, Tuesday, 12'th May 2020
This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.
BMO Capital Maintains Market Perform on Fate Therapeutics, Raises Price Target to $29
02:24pm, Tuesday, 12'th May 2020Edited Transcript of FATE earnings conference call or presentation 11-May-20 9:00pm GMT
01:30pm, Tuesday, 12'th May 2020
Q1 2020 Fate Therapeutics Inc Earnings Call
U.S. RESEARCH ROUNDUP-Digital Realty Trust, Pilgrims Pride, Terraform Power
07:26am, Tuesday, 12'th May 2020
Wall Street securities analysts revised their ratings and price targets on
several U.S.-listed companies, including Digital Realty Trust, Pilgrims Pride and Terraform Power,
on Tuesday.
HIGH
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2020 Results - Earnings Call Transcript
04:38am, Tuesday, 12'th May 2020
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2020 Earnings Conference Call May 11, 2020 5:00 PM ET Company Participants Scott Wolchko - President & Chief Execut
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
09:15pm, Monday, 11'th May 2020
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -15.79% and 21.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
